ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value27-Oct-25 39,856 €907.51 €36,169,766 28-Oct-25 39,890 €906.74 €36,169,942 29-Oct-25 39,349 €919.20 €36,169,404 30-Oct-25 38,889 €930.08 €36,170,029 31-Oct-25 39,045 €926.37 €36,170,085 ASML’s current share buyback program was announced on 10 Nove...
UCB's Bimzelx is well-positioned with strong 3-year data in HS and competitive performance across PsO, PsA, and axSpA, supporting our peak sales estimate of €5.9b by 2030. Despite premium forward P/E multiples, UCB's projected EPS CAGR (2025–2029), being >3x that of peers, means UCB continues to be an attractive name to own. Earlier in the pipeline, our deep dive into the atopic dermatitis (AD) landscape shows that phase 2a data for galovokimig is promising, with plans to advance to phase 2b. Ac...
KBC Group: KBC’s capital remains well above the new minimum capital requirements KBC has been informed by the European Central Bank (ECB) of its new minimum capital requirements. Following the Supervisory Review and Evaluation Process (SREP) performed for 2025, the fully loaded overall CET1 requirement for KBC Group (under the Danish Compromise) has been lowered from 10.88% as of 4Q24 (SREP 2024) to 10.85% as of 3Q25 (SREP 2025). The new requirement consists of a Pillar 1 Requirement of 4.50%, a Pillar 2 Requirement (P2R) of 1.10%1, a capital conservation buffer of 2.50%, the O-SII (other...
KBC Groep: Het kapitaal van KBC blijft ruim boven de nieuwe minimumkapitaalvereisten KBC is door de Europese Centrale Bank (ECB) op de hoogte gesteld van haar nieuwe minimumkapitaalvereisten. Naar aanleiding van het Supervisory Review and Evaluation Process (SREP) dat werd uitgevoerd voor 2025, is de fully loaded totale CET1-vereiste voor KBC Groep (volgens de Deense Compromismethode) verlaagd van 10,88% vanaf 4KW24 (SREP 2024) naar 10,85% vanaf 3KW25 (SREP 2025). De nieuwe vereiste bestaat uit een Pijler 1-vereiste van 4,50%, een Pijler 2-vereiste (P2R) van 1,10%1 , een kapitaalinstandh...
KBC Groupe: Le capital de KBC reste largement supérieur aux nouvelles exigences minimales La Banque centrale européenne (BCE) a officiellement informé KBC de ses nouvelles exigences minimales en matière de capital. À la suite du processus de révision et d'évaluation prudentielle (SREP) effectué pour 2025, l'exigence CET1 globale à pleine charge pour le groupe KBC (selon la méthode du compromis danois) a été abaissée de 10,88 % au 4T24 (SREP 2024) à 10,85 % au 3T25 (SREP 2025). Les nouvelles exigences se composent d'une exigence de pilier 1 de 4,50 %, d'une exigence de pilier 2 (P2R) de 1...
AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...
A director at Safran S.A. sold 456 shares at 305.000EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
As a follow up to our cheat sheet summarizing the cost structure of a 1GW datacenter, we estimate today on a single slide WFE required to produce semiconductors for a 1 GW datacenter, with our usual important caveat: WFE spending is driven by the growth of production capacity. In other words, one spends once on WFE to build a 1GW datacenter many times over.
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery. Analyzing real-world data from over 22,000 patients in the Premier PINC AI™ Healthcare Database, the ana...
ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. Date Total repurchased shares Weighted average price Total repurchased value 20-Oct-25 40,792 886.69 36,169,813.61 21-Oct-25 40,622 890.40 36,169,926.29 22-Oct-25 40,808 886.35 36,170,011.65 23-Oct-25 41,314 875.48 36,169,374.15 24-Oct-25 40,404 895.20 36,169,689.08 ...
UCB announced new 3-year data for Bimzelx in adults with active psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) at ACR 2025. The results show sustained responses in both patient groups, and appear competitive vs. other biologics e.g. Cosentyx in cross-trial comparison. Overall supportive data that should maintain Bimzelx' commercial momentum. ACCUMULATE maintained.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.